Hiranandani Healthcare Pvt, Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





all fortist, e. et e.

UHID	5652362	Date	10/12/20	022	
CHARD	Mr.Ganesh Gejage	Sex	Male	Age	36
OPD	Opthal 14	Healt	h Check I	Jp	

Clr. Bury Shi.

Drug allergy: -> Not kown
Sys illness: -> Col 4

Mc No.

0-jall 5 x 6/6

Report of the second of the se

Phus 6/6
Phus 6/6
No

J-0.1. 16.0

Teurs 1 1 1 6 mls

ì

1

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 - A. Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 9 | 7

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



Date	10/12/20)22	
	Male	Age	36
1			<u>.</u>
Healt	h Check l	J p	- 00000
	Sex	Sex Male	7.7 1 4.00

Drug allergy: Sys illness:

Adv. Alling -







PATIENT NAME: MR. GANESH AABA GEJAGE

FH.5652362 PATIENT ID:

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002

36 Years AGE:

SEX: Male

ABHA NO :

Biological Reference Interval

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

Final

REFERRING DOCTOR: SELF

Results

Units

KIDNEY PANEL - 1

Test Report Status

BLOOD UREA NITROGEN (BUN), SERUM


BLOOD UREA NITROGEN

7

6 - 20

mg/dL

METHOD: UREASE - UV



CREATININE EGFR- EPI

CREATININE

1.02

0.90 - 1.30

mg/dL

METHOD: ALKALINE PICRATE KINETIC JAFFES

AGE

36

years

GLOMERULAR FILTRATION RATE (MALE)

97.68

Refer Interpretation Below

mL/min/1.73m2

METHOD: CALCULATED PARAMETER

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID:

FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002

AGE: 36 Years

SEX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED: 10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF


Test Report Status

Final

Results

Biological Reference Interval

Units



BUN/CREAT RATIO			
BUN/CREAT RATIO	6.86		5.00 - 15.00
METHOD: CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	7.7	High	3.5 - 7.2
METHOD : URICASE UV			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.5		6.4 - 8.2
METHOD: BIURET			Ŷ
ALBUMIN, SERUM			
ALBUMIN	3.9		3.4 - 5.0
METHOD: BCP DYE BINDING			
GLOBULIN			
GLOBULIN	3.6		2.0 - 4.1
METHOD: CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141		136 - 145
METHOD: ISE INDIRECT			
POTASSIUM, SERUM	4.40	35)	3.50 - 5.10
METHOD: ISE INDIRECT	2020 <u>-</u>		
CHLORIDE, SERUM	102		98 - 107
METHOD: ISE INDIRECT			

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report

Page 2 Of 14 Patient Ref. No. 22000000814269







PATIENT NAME: MR. GANESH AABA GEJAGE

CLIENT PATIENT ID: UID:5652362 FH.5652362

PATIENT ID: SEX: Male

ABHA NO: AGE: 36 Years 10/12/2022 15:55:42 0022VL002002 ACCESSION NO: RECEIVED: 10/12/2022 09:50:08 REPORTED:

DRAWN: 10/12/2022 09:49:00 REFERRING DOCTOR: SELF CLIENT NAME : FORTIS VASHI-CHC -SPLZD

Units Biological Reference Interval Results Test Report Status Final

Interpretation(s)

Interpretation(s)
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Incre

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include the renal (High p Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE EGFR- EPI-CREATININE EGFR- EPIGFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney function than serum creatinine alone.

Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated of the complex comp

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

ALBUMIN, SERUMHuman serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID: FH.5652362 CLIENT PATIENT ID: UID:5652362

ACCESSION NO: **0022VL002002** AGE: 36 Years DRAWN: 10/12/2022 09:49:00 RECEIVED: 10/12/2022 09:49:00

GE: 36 Years SEX: Male RECEIVED: 10/12/2022 09:50:08 ABHA NO:

REPORTED: 10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLIENT NAME : FOR 115	VASHI-CHE D. ===			
	-1.221	Results	Biological Reference Interval	Units
Test Report Status	<u>Final</u>			

	HAEMATOLOGY		
CBC-5, EDTA WHOLE BLOOD			
BLOOD COUNTS, EDTA WHOLE BLOOD		13.0 - 17.0	g/dL
HEMOGLOBIN (HB)	14.6	13.0 - 17.0	****
METHOD : SPECTROPHOTOMETRY	8	4.5 - 5.5	mil/µL
RED BLOOD CELL (RBC) COUNT	5.49	4.5 - 5.5	
METHOD : ELECTRICAL IMPEDANCE	26 V S	4.0 - 10.0	thou/µL
WHITE BLOOD CELL (WBC) COUNT	7.94	4.0 - 10.0	Of the field of the Control of the C
METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS	S)CYTOMETRY	150 - 410	thou/µL
PLATELET COUNT	379	130 - 410	2702000 e4207 • \$4.000
METHOD: ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES		40 F0	%
HEMATOCRIT (PCV)	43.1	40 - 50	
METHOD : CALCULATED PARAMETER		Low 83 - 101	fL
MEAN CORPUSCULAR VOLUME (MCV)	78.5	row 83 - 101	-
METHOD : CALCULATED PARAMETER		Low 27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.5	LOW 27.0 - 32.0	
METHOD: CALCULATED PARAMETER		31.5 - 34.5	g/dL
MEAN CORPUSCULAR HEMOGLOBIN	33.8	31.5 - 34.5	27 865
CONCENTRATION(MCHC)			
METHOD : CALCULATED PARAMETER	13.8	11.6 - 14.0	%
RED CELL DISTRIBUTION WIDTH (RDW)	See of the second		
METHOD: CALCULATED PARAMETER	14.3		
MENTZER INDEX	9.0	6.8 - 10.9	fL
MEAN PLATELET VOLUME (MPV)	5.0		
METHOD : CALCULATED PARAMETER			
WBC DIFFERENTIAL COUNT	50	40 - 80	%
NEUTROPHILS	50		
METHOD: FLOW CYTOMETRY	40	20 - 40	%
LYMPHOCYTES	40	0 000 0 0007X	
METHOD: FLOW CYTOMETRY	06	2 - 10	%
MONOCYTES	06		
METHOD: FLOW CYTOMETRY	0.4	1 - 6	%
EOSINOPHILS	04	5 7	
METHOD: FLOW CYTOMETRY	00	0 - 2	%
BASOPHILS	00	od st—state t	
METHOD: FLOW CYTOMETRY	2.07	2.0 - 7.0	thou/µ
ABSOLUTE NEUTROPHIL COUNT	3.97	##13#0 *0.503*0	
METHOD: CALCULATED PARAMETER	2.10	High 1.0 - 3.0	thou/µ
ABSOLUTE LYMPHOCYTE COUNT	3.18		Page 4 Of 1
SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE	POAD PART		


SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID: FH.5652362 CLIENT PATIENT ID: UID:5652362

ACCESSION NO:

0022VL002002

36 Years AGE:

SEX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED :

10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SFLF

Test Report Status <u>Final</u>	Results		Biological Reference	e Interval Units
METHOD: CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT	0.48		0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT	0.32		0.02 - 0.50	thou/µL
METHOD: CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT	0	Low	0.02 - 0.10	thou/µL
METHOD: CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.2			
METHOD: CALCULATED PARAMETER				
MODBUOLOCY				

MORPHOLOGY

RRC

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

METHOD: MICROSCOPIC EXAMINATION

WBC

NORMAL MORPHOLOGY

METHOD: MICROSCOPIC EXAMINATION

PLATELETS

ADEQUATE

METHOD: MICROSCOPIC EXAMINATION

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

F.S.R

05

0 - 14

mm at 1 hr

METHOD: WESTERGREN METHOD

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR), is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Polkilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details





Scan to View Report







PATIENT NAME: MR. GANESH AABA GEJAGE

PATTENT ID :

FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002

36 Years AGE:

SFX: Male

ABHA NO :

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

Test Report Status

Final

Results

Biological Reference Interval

the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE A

RH TYPE

METHOD: TUBE AGGLUTINATION

POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

BIO CHEMISTRY

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

153

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES

114

< 150 Normal

mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL

34

Low < 40 Low

mg/dL

>/=60 High

METHOD: DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT

NON HDL CHOLESTEROL

103

119

4.5

mg/dL

< 100 Optimal 100 - 129 Near or above optimal

130 - 159 Borderline High

160 - 189 High

>/= 190 Very High

Desirable: Less than 130

mg/dL

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

METHOD: CALCULATED PARAMETER CHOL/HDL RATIO

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

High 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk

> 11.0 High Risk

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA



Scan to View Details



Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

CLIENT PATIENT ID: UID:5652362 PATIENT ID: FH.5652362

ACCESSION NO: 0022VL002002

SEX: Male AGE: 36 Years


ABHA NO:


REPORTED: 10/12/2022 15:55:42 RECEIVED: 10/12/2022 09:50:08

DRAWN: 10/12/2022 09:49:00 CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CELENT MAILE : I CALLED THE				$\overline{}$
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval	_
METHOD: CALCULATED PARAMETER LDL/HDL RATIO	3.0	0.5 - 3.0 Desirable/L 3.1 - 6.0 Borderline/I >6.0 High Risk	ow Risk Moderate Risk	
METHOD: CALCULATED PARAMETER VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER	22.8	= 30.0</th <th>mg/dL</th> <th>ø</th>	mg/dL	ø






SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID:

FH.5652362

CLIENT PATIENT ID: UID:5652362

REFERRING DOCTOR: SELF

ACCESSION NO: 0022VL002002

36 Years AGE:

SEX: Male

ABHA NO:

10/12/2022 15:55:42

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED :


Test Report Status


CLIENT NAME : FORTIS VASHI-CHC -SPLZD

Final

Results

Biological Reference Interval





LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL

0.62

0.2 - 1.0

mg/dL

METHOD: JENDRASSIK AND GROFF

0.14

0.0 - 0.2


mg/dL

BILIRUBIN, DIRECT

METHOD: JENDRASSIK AND GROFF

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA





Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID : FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002 AGE: 36 Years

SEX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED: 10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD	REFERRING DO	CTOR: SELF	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval
BILIRUBIN, INDIRECT	0.48	0.1 - 1.0	mg/dL
METHOD: CALCULATED PARAMETER TOTAL PROTEIN	7.5	6.4 - 8.2	g/dL
METHOD: BIURET ALBUMIN	3.9	3.4 - 5.0	g/dL
METHOD: BCP DYE BINDING GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.1	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE (AST/SGOT)	19	15 - 37	U/L
METHOD: UV WITH P5P ALANINE AMINOTRANSFERASE (ALT/SGPT)	41	< 45.0	U/L
METHOD: UV WITH PSP ALKALINE PHOSPHATASE	123	High 30 - 120	U/L
METHOD: PNPP-ANP GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	37	15 - 85	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE -PYRUVATE	132	100 - 190	U/L
GLUCOSE FASTING, FLUORIDE PLASMA FBS (FASTING BLOOD SUGAR) METHOD: HEXOKINASE	103	High 74 - 99	mg/dL







Scan to View Details

Page 9 Of 14







PATIENT NAME: MR. GANESH AABA GEJAGE

FH.5652362 PATIENT ID:

CLIENT PATIENT ID: UID:5652362

0022VL002002

SEX: Male AGE: 36 Years

ABHA NO:

10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08


REPORTED:

ACCESSION NO:

REFERRING DOCTOR: SELF

Test Report Status Final Results

Biological Reference Interval



GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C

6.2

High Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4

Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) METHOD: CALCULATED PARAMETER

131.2

High < 116.0

mg/dL

%

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,





Scan to View Report









PATIENT NAME: MR. GANESH AABA GEJAGE

FH.5652362 PATTENT ID:

CLIENT PATIENT ID: UID:5652362

ACCESSION NO:

0022VL002002

AGE: 36 Years

SFX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

10/12/2022 15:55:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD


REFERRING DOCTOR: SELF

Test Report Status

<u>Final</u>

Results

Biological Reference Interval



Interpretation(s)
LIPID PROFILE, SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don to cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

't need into triglycerides, which are stored in fat cells. High Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn" Serum Inglyceride are a type of rat in the blood. When you ear, your body converts any calories it doesn. It need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult. LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give Bilirubin is a yellowish pigment round in bile and is a breakdown product of normal name catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

Scan to View Details



Scan to View Report

Page 11 Of 14









PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID: FH.5652362 CLIENT PATIENT ID: UID:5652362

ACCESSION NO:

0022VL002002

AGE: 36 Years SEX: Male

ABHA NO:

10/12/2022 15:55:42

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

Test Report Status

Final

Results

Biological Reference Interval

there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) billrubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreased in the disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

ntifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

III. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV. Interference of hemoglobinopathies in HbA1c estimation is seen in a Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy

CLINICAL PATH

URINALYSIS

PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD: PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL


SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10.

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

















PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID: FH.5652362

DRAWN: 10/12/2022 09:49:00

CLIENT PATIENT ID: UID:5652362

REFERRING DOCTOR: SELF

ACCESSION NO: 0022VL002002

AGE: 36 Years SEX: Male

ABHA NO :

10/12/2022 15:55:42

RECEIVED: 10/12/2022 09:50:08

REPORTED:

Test Report Status

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

Final

Results

Biological Reference Interval

CHEMICAL EXAMINATION, URINE

PH

6.0

4.7 - 7.5

SPECIFIC GRAVITY

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

<=1.005

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

PROTEIN

NOT DETECTED

NOT DETECTED

GLUCOSE

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

NOT DETECTED

NOT DETECTED

KETONES

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

NORMAL

UROBILINOGEN

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NORMAL

NOT DETECTED

NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

NOT DETECTED

NOT DETECTED

LEUKOCYTE ESTERASE METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

0-1

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

EPITHELIAL CELLS

METHOD: MICROSCOPIC EXAMINATION

0-1

0-5

/HPF

CASTS

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

CRYSTALS

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION BACTERIA

NOT DETECTED

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST

NOT DETECTED

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

Tel: 022-39199222,022-49723322,

REMARKS

URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT

Interpretation(s)

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA



Scan to View Details











PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID: FH.5652362 CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002 AGE:

36 Years

SEX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

10/12/2022 15:55:42

CLIENT NAME: FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

Test Report Status

Final

Results

Biological Reference Interval

End Of Report Please visit www.srlworld.com for related Test Information for this accession


Dr.Akta Dubey

Counsultant Pathologist

Dr. Rekha Nair, MD

Microbiologist













PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID:

FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002 AGE: 36 Years

SEX: Male

ABHA NO:

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED: 10/12/2022 14:44:11

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

T4

161.8

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

10.93

5.1 - 14.1

µg/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY TSH (ULTRASENSITIVE)

1.570

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

0.270 - 4.200

µIU/mL

Interpretation(s)

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA

Tel: 9111591115,



Scan to View Details











PATIENT NAME: MR. GANESH AABA GEJAGE

PATIENT ID:

FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002002

36 Years AGE:

SEX: Male

ABHA NO :

DRAWN: 10/12/2022 09:49:00

RECEIVED: 10/12/2022 09:50:08

REPORTED:

10/12/2022 14:44:11

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

0.361

< 1.4

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.

- PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the

For all first detection of the second of the detecting residual disease and early recurrence of tumor.

elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA. traise positive) levels persisting up to 3 weeks.

- As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference (false positive) levels persisting up to 3 weeks.

range can be used as a guide lines-

Age of male Reference range (ng/ml) 0-2.5

40-49 years 50-59 years

60-69 years 70-79 years 0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)

References- Teitz , textbook of clinical chemiistry, 4th edition) 2. Wallach's Interpretation of Diagnostic Tests

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam **Consultant Pathologist**

Birmbadlam

SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,



Scan to View Details



Scan to View Report









PATIENT NAME: MR. MR.GANESH AABA GEJAGE

PATIENT ID: FH.5652362 CLIENT PATIENT ID: UID:5652362

ACCESSION NO:

0022VL002082 AGE: 36 Years

SEX: Male

ABHA NO:

REPORTED:

10/12/2022 14:15:21

DRAWN: 10/12/2022 12:59:00

RECEIVED: 10/12/2022 12:59:55

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:5652362 REQNO-1342044

CORP-OPD

BILLNO-1501220PCR062794 BILLNO-1501220PCR062794

Biological Reference Interval Units Results **Test Report Status** Final

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA


PPBS(POST PRANDIAL BLOOD SUGAR)

188

High 70 - 139

mg/dL

METHOD: HEXOKINASE



Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin response & sensitivity etc. Additional test HbA1c treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

End Of Report Please visit www.srlworld.com for related Test Information for this accession

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MR. MR.GANESH AABA GEJAGE

PATIENT ID:

FH.5652362

CLIENT PATIENT ID: UID:5652362

ACCESSION NO: 0022VL002082

AGE: 36 Years

SEX: Male

ABHA NO:

RECEIVED: 10/12/2022 12:59:55

REPORTED:

10/12/2022 14:15:21

DRAWN: 10/12/2022 12:59:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:5652362 REQNO-1342044

CORP-OPD

BILLNO-1501220PCR062794 BILLNO-1501220PCR062794

Test Report Status

Final

Results

Biological Reference Interval

Units

Dr.Akta Dubey **Counsultant Pathologist**

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,








Scan to View Report





Mini Sea Shure Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF NIC

Date: 10/Dec/2022

Name: Mr. Ganesh Aaba Gejage

Age | Sex: 36 YEAR(S) | Male Order Station : FO-OPD

Bed Name:

UHID | Episode No : 5652362 | 62168/22/1501

Order No | Order Date: 1501/PN/OP/2212/132140 | 10-Dec-2022 Admitted On | Reporting Date : 10-Dec-2022 17:43:21

Order Doctor Name: Dr.SELF.

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- · No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- · No left ventricle diastolic dysfunction.
- · No left ventricle Hypertrophy. No left ventricle dilatation.
- Structurally normal valves.
- · No mitral regurgitation.
- · No aortic regurgitation. No aortic stenosis.
- · No tricuspid regurgitation. No pulmonary hypertension.
- · Intact IAS and IVS.
- No left ventricle clot/vegetation/pericardial effusion.
- · Normal right atrium and right ventricle dimensions.
- Normal left atrium and left ventricle dimension.
- · Normal right ventricle systolic function. No hepatic congestion.

M-MODE MEASUREMENTS:

LA	38	mm
AO Root	32	mm
AO CUSP SEP	21	mm
LVID (s)	27	mm
LVID (d)	44	mm
IVS (d)	09	mm
LVPW (d)	10	mm
RVID (d)	29	mm
RA	30	mm
LVEF	60	%

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF NIC

Date: 10/Dec/2022

Name: Mr. Ganesh Aaba Gejage

Age | Sex: 36 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No: 5652362 | 62168/22/1501

Order No | Order Date: 1501/PN/OP/2212/132140 | 10-Dec-2022

Admitted On | Reporting Date: 10-Dec-2022 17:43:21

Order Doctor Name: Dr.SELF.

DOPPLER STUDY:

E WAVE VELOCITY: 0.9 m/sec. A WAVE VELOCITY: 0.6 m/sec

E/A RATIO:1.6

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
MITRAL VALVE	N			Nil
AORTIC VALVE	05			Nil
TRICUSPID VALVE	N			Nil
PULMONARY VALVE	2.0			Nil

Final Impression:

Normal 2 Dimensional and colour doppler echocardiography study.

DR. PRASHANT PAWAR

DNB(MED), DNB (CARDIOLOGY)

mirananuani meaithcare PVt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 10/Dec/2022

Name: Mr. Ganesh Aaba Gejage Age | Sex: 36 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No: 5652362 | 62168/22/1501 Order No | Order Date: 1501/PN/OP/2212/132140 | 10-Dec-2022 Admitted On | Reporting Date: 10-Dec-2022 12:40:59

Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGINI SHAH

DMRD., DNB. (Radiologist)

milananuani meaithcare PVt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D







Date: 10/Dec/2022

DEPARTMENT OF RADIOLOGY

Name: Mr. Ganesh Aaba Gejage Age | Sex: 36 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No : 5652362 | 62168/22/1501

Order No | Order Date: 1501/PN/OP/2212/132140 | 10-Dec-2022 Admitted On | Reporting Date : 10-Dec-2022 14:00:17

Order Doctor Name : Dr.SELF .

US-WHOLE ABDOMEN

LIVER is normal in size (14.4 cm) and shows raised echogenicity. Intrahepatic portal and biliary systems are normal. No focal lesion is seen in liver. Portal vein appears normal.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. CBD appears normal in caliber.

SPLEEN is normal in size (9.6 cm) and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 9.6 x 4.6 cm.

Left kidney measures 9.6 x 4.8 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical mass/calculi.

PROSTATE is normal in size & echogenicity. It measures ~ 14 cc in volume.

No evidence of ascites.

IMPRESSION:

· Fatty infiltration of liver.

DR. VIVER MANE

MBBS., DMRE. (Radiologist)